Literature DB >> 23948362

Narcotic prescribing habits and other methods of pain control by oral and maxillofacial surgeons after impacted third molar removal.

Ibrahim Mutlu1, A Omar Abubaker, Daniel M Laskin.   

Abstract

PURPOSE: It has been suggested that a source of narcotics used for nonmedical purposes by young adults is the unused opioids prescribed for the management of pain after the removal of impacted third molars. The purpose of the present study was to determine whether oral and maxillofacial surgeons routinely prescribe larger amounts of a narcotic than would generally be needed for adequate postoperative pain control. A secondary goal was to determine whether they use methods other than analgesic drugs to minimize postoperative pain and thereby reduce the amount of narcotic that might be needed. PATIENTS AND METHODS: An 8-question survey was sent to 100 randomly selected oral and maxillofacial surgeon members of the American Association of Oral and Maxillofacial Surgeons in each of the 6 association districts. The questions asked were related to whether a narcotic was routinely prescribed for patients who have had impacted teeth removed, the most common drug used, and the dosage and number of tablets prescribed. The participants were also asked whether they had pretreated patients with a nonsteroidal anti-inflammatory drug or had prescribed one along with the narcotic, had injected a steroid, or had used a long-lasting local anesthetic postoperatively.
RESULTS: Only 2 of the 384 respondents stated that they did not prescribe a narcotic for patients who had had impacted teeth removed. Hydrocodone (5 mg) was the most frequently prescribed narcotic. The number of tablets varied from 10 to 40, but the most common number was 20 tablets. However, 80 respondents (22%) prescribed more, with 40 prescribing 30 tablets. Also, 80% of the respondents injected their patients with a steroid, and 62% injected a long-lasting local anesthetic postoperatively. Only 34% pretreated their patients with a nonsteroidal anti-inflammatory drug, but 66% recommended such use postoperatively.
CONCLUSIONS: Most oral and maxillofacial surgeons prescribe analgesic drugs of an appropriate type and dosage and use proper adjunctive pain control measures to supplement these drugs. However, our findings also indicated that more than 20% prescribe more tablets than would generally be necessary to control the postoperative pain after the removal of impacted third molars. This could be a source of drug diversion and nonmedical use by young adults and should be avoided.
Copyright © 2013 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23948362     DOI: 10.1016/j.joms.2013.04.031

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  18 in total

1.  Addressing the Opioid Epidemic: Impact of Opioid Prescribing Protocol at the University of Minnesota School of Dentistry.

Authors:  Robert Nadeau; Kristopher Hasstedt; Ashley Brooke Sunstrum; Chad Wagner; Harold Tu
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2018-05-15

2.  Opioid prescribing patterns after dental visits among beneficiaries of Medicaid in Washington state in 2014 and 2015.

Authors:  Enihomo Obadan-Udoh; Nicoleta Lupulescu-Mann; Christina J Charlesworth; Ulrike Muench; Matthew Jura; Hyunjee Kim; Eli Schwarz; Elizabeth Mertz; Benjamin C Sun
Journal:  J Am Dent Assoc       Date:  2019-04       Impact factor: 3.634

3.  Surgical interns: Preparedness for opioid prescribing before and after a training intervention.

Authors:  Michael J Nooromid; Neel A Mansukhani; Benjamin W Deschner; Simon Moradian; Nabil Issa; Karen J Ho; Jonah J Stulberg
Journal:  Am J Surg       Date:  2017-11-20       Impact factor: 2.565

4.  Variation in post-discharge opioid prescriptions among members of a surgical team.

Authors:  Eddie Blay; Michael J Nooromid; Karl Y Bilimoria; Jane L Holl; Bruce Lambert; Julie K Johnson; Jonah J Stulberg
Journal:  Am J Surg       Date:  2017-11-01       Impact factor: 2.565

5.  Opioid Prescribing Practice and Needs in Thyroid and Parathyroid Surgery.

Authors:  Maisie Shindo; James Lim; Enrique Leon; Lauren Moneta; Ryan Li; Lourdes Quintanilla-Dieck
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-12-01       Impact factor: 6.223

6.  Postoperative opioid-prescribing patterns among surgeons and residents at university-affiliated hospitals: a survey study

Authors:  Akash Goel; Adina Feinberg; Brandon McGuiness; Sav Brar; Sanjho Srikandarajah; Emily Pearsall; Robin McLeod; Hance Clarke
Journal:  Can J Surg       Date:  2020-01-09       Impact factor: 2.089

7.  Postoperative Pain Control and Opioid Usage Patterns among Patients Undergoing Thyroidectomy and Parathyroidectomy.

Authors:  Theresa Tharakan; Sydney Jiang; Judd Fastenberg; Thomas J Ow; Bradley Schiff; Richard V Smith; Vikas Mehta
Journal:  Otolaryngol Head Neck Surg       Date:  2018-10-16       Impact factor: 3.497

8.  Training experiences regarding pain management, addiction, and drug diversion of dentists enrolled in the National Dental Practice-Based Research Network.

Authors:  Jenna L McCauley; Stephanie Reyes; Cyril Meyerowitz; Valeria V Gordan; D Brad Rindal; Gregg H Gilbert; Renata S Leite; Roger B Fillingim; Kathleen T Brady
Journal:  Subst Abus       Date:  2019-03-04       Impact factor: 3.716

9.  Opioid prescribing and risk mitigation implementation in the management of acute pain: Results from The National Dental Practice-Based Research Network.

Authors:  Jenna L McCauley; Renata S Leite; Valeria V Gordan; Roger B Fillingim; Gregg H Gilbert; Cyril Meyerowitz; David Cochran; D Brad Rindal; Kathleen T Brady
Journal:  J Am Dent Assoc       Date:  2018-03-15       Impact factor: 3.634

10.  Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010.

Authors:  James A Baker; Jerry Avorn; Raisa Levin; Brian T Bateman
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.